US HB8467 | 2019-2020 | 116th Congress
Status
Spectrum: Bipartisan Bill
Status: Introduced on September 30 2020 - 25% progression, died in committee
Action: 2020-09-30 - Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on September 30 2020 - 25% progression, died in committee
Action: 2020-09-30 - Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Prohibits coverage exclusions or limitations under the Medicare prescription drug benefit, Medicaid, or private health insurance of certain drugs that are used to treat rare diseases or conditions (i.e., diseases or conditions that affect 200,000 or fewer individuals and that are supported by the National Institutes of Health Rare Diseases Clinical Research Network).
Title
Access to Rare Indications Act of 2020
Sponsors
Rep. Mike Thompson [D-CA] | Rep. Mike Kelly [R-PA] |
History
Date | Chamber | Action |
---|---|---|
2020-09-30 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
2020-09-30 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
2020-09-30 | House | Introduced in House |
Subjects
Drug therapy
Employee benefits and pensions
Health
Health care costs and insurance
Health care coverage and access
Insurance industry and regulation
Medicaid
Medicare
Prescription drugs
Employee benefits and pensions
Health
Health care costs and insurance
Health care coverage and access
Insurance industry and regulation
Medicaid
Medicare
Prescription drugs
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/116th-congress/house-bill/8467/all-info |
Text | https://www.congress.gov/116/bills/hr8467/BILLS-116hr8467ih.pdf |